| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Vincerx Pharma, Inc.$0.01
+0 (+1.18%)
F 15Pipeline Score Overvalued Biotech · Clinical
Market Cap
523.43 K
EPS
-19.56
P/E Ratio
-
Value Trade
34.27
SEC Financials
Q1 2025Dilution Risk
R&D Expenses
1.02 M
Operating CF
-4.45 M
Total Assets
4.69 M
Total Liabilities
2.62 M
Equity
2.07 M
D/E Ratio
12,345
-61.54 %
Week
-83.36 %
1 Month
-96.2 %
3 Month
-98.63 %
6 Month
-99.95 %
5 Year
-99.95 %
All Time
Cash Data
Cash Position
4.44 M
Monthly Burn
1.49 M
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2025
Overview
Volume
2.67 K
52 Week Range
1.18 - 187.44
% held by Insiders
4.11 %
% held by Institutions
4.24 %
Enterprise Value
-6.27 M
Total Shares
2.24 M
Short %
2.94 %
Float Shares
1.54 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F15
Pipeline Score $0M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.4x
rNPV / MCap Top 11%
Micro Cap (rank 806 of 905)
Percentile RankVincerx Pharma, Inc. has significant pipeline risk (15/100), with $124M risk-adjusted pipeline value, led by VIP152 in Neoplasms (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP152 Small molecule | Neoplasms | Phase 1 | NCT02635672 | 5% | $47M | COMPLETED | 110 | - | - | Nov 11, 2024 | - | Nov 15, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VINC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Vincerx Pharma, Inc. (VINC) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
VINC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VINC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VINC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VINC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
VINC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How VINC ranks across every disease it competes inCompetitive Position is a premium feature
See how VINC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial